Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Potential effects of nicotine on glioblastoma and chemoradiotherapy: a review.

McConnell DD, Carr SB, Litofsky NS.

Expert Rev Neurother. 2019 Jun;19(6):545-555. doi: 10.1080/14737175.2019.1617701. Epub 2019 May 17.

PMID:
31092064
2.

Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.

Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Yung WKA, Prados MD, Bruner JM, Chang SM, Kyritsis AP, Gleason MJ, Hess KR.

Clin Cancer Res. 2000 Oct;6(10):3878-84.

3.

Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.

Kim SH, Yoo H, Chang JH, Kim CY, Chung DS, Kim SH, Park SH, Lee YS, Yang SH.

J Korean Med Sci. 2018 May 10;33(24):e167. doi: 10.3346/jkms.2018.33.e167. eCollection 2018 Jun 11.

4.

Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells.

Wu L, Yang L, Xiong Y, Guo H, Shen X, Cheng Z, Zhang Y, Gao Z, Zhu X.

Tumour Biol. 2014 Dec;35(12):12327-37. doi: 10.1007/s13277-014-2545-1. Epub 2014 Sep 23.

PMID:
25245332
5.

Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.

Conti S, Vexler A, Edry-Botzer L, Kalich-Philosoph L, Corn BW, Shtraus N, Meir Y, Hagoel L, Shtabsky A, Marmor S, Earon G, Lev-Ari S.

PLoS One. 2018 Jul 3;13(7):e0198627. doi: 10.1371/journal.pone.0198627. eCollection 2018.

6.

Vaping versus Smoking: A Quest for Efficacy and Safety of E-cigarette.

Rehan HS, Maini J, Hungin APS.

Curr Drug Saf. 2018;13(2):92-101. doi: 10.2174/1574886313666180227110556. Review.

PMID:
29485005
7.

Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis.

Zarnett OJ, Sahgal A, Gosio J, Perry J, Berger MS, Chang S, Das S.

JAMA Neurol. 2015 May;72(5):589-96. doi: 10.1001/jamaneurol.2014.3739. Review.

PMID:
25822375
8.
9.

Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience.

Lukács G, Tóth Z, Sipos D, Csima M, Hadjiev J, Bajzik G, Cselik Z, Semjén D, Repa I, Kovács Á.

Ideggyogy Sz. 2018 Mar 30;71(3-04):95-103. doi: 10.18071/isz.71.0095.

PMID:
29889468
10.

Procarbazine, lomustine and vincristine for recurrent high-grade glioma.

Parasramka S, Talari G, Rosenfeld M, Guo J, Villano JL.

Cochrane Database Syst Rev. 2017 Jul 26;7:CD011773. doi: 10.1002/14651858.CD011773.pub2. Review.

11.
13.

Survival and prognostic factors for glioblastoma multiforme: Retrospective single-institutional study.

Ghosh M, Shubham S, Mandal K, Trivedi V, Chauhan R, Naseera S.

Indian J Cancer. 2017 Jan-Mar;54(1):362-367. doi: 10.4103/ijc.IJC_157_17.

14.

Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.

St-Coeur PD, Poitras JJ, Cuperlovic-Culf M, Touaibia M, Morin P Jr.

J Neurooncol. 2015 Oct;125(1):91-102. doi: 10.1007/s11060-015-1899-6. Epub 2015 Aug 28.

PMID:
26311249
15.

Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.

Jakacki RI, Cohen KJ, Buxton A, Krailo MD, Burger PC, Rosenblum MK, Brat DJ, Hamilton RL, Eckel SP, Zhou T, Lavey RS, Pollack IF.

Neuro Oncol. 2016 Oct;18(10):1442-50. doi: 10.1093/neuonc/now038. Epub 2016 Mar 22.

16.

Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.

Kuhnhenn J, Kowalski T, Steenken S, Ostermann K, Schlegel U.

J Neurooncol. 2012 Sep;109(2):433-8. doi: 10.1007/s11060-012-0913-5. Epub 2012 Jun 29.

PMID:
22744756
17.

Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.

Levin VA, Wara WM, Davis RL, Vestnys P, Resser KJ, Yatsko K, Nutik S, Gutin PH, Wilson CB.

J Neurosurg. 1985 Aug;63(2):218-23.

PMID:
2991486
18.

Factors affecting the survival of patients with glioblastoma multiforme.

Nikolov V, Stojanovic M, Kostic A, Radisavljevic M, Simonovic N, Jelenkovic B, Berilazic L.

J BUON. 2018 Jan-Feb;23(1):173-178.

19.

Distinct response to GDF15 knockdown in pediatric and adult glioblastoma cell lines.

Baroni M, Marie SKN, Fedatto PF, Andrade AF, Suazo VK, Cruzeiro GAV, de Paula Queiroz R, Tone LG, Scrideli CA.

J Neurooncol. 2018 Aug;139(1):51-60. doi: 10.1007/s11060-018-2853-1. Epub 2018 Apr 18.

PMID:
29671197
20.

Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic astrocytoma and glioblastoma multiforme.

Krishnasamy S, Vokes EE, Dohrmann GJ, Mick R, Garcia JC, Kolker JD, Wollmann RL, Hekmatpanah J, Weichselbaum RR.

Cancer Invest. 1995;13(5):453-9.

PMID:
7552809

Supplemental Content

Support Center